ClinicalTrials.gg
Not yet recruitingNCT07948213TYPHON-PUpdated Nov 19, 2026

Transformed B-cell Lymphoma : Clonal Evolution, Microenvironment Remodeling and Therapeutic Targets Discovery; Prospective Program

An observational study in Transformed B-Cell Lymphoma, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma and Transformed Follic Lymph to Diff Large B-Cell Lymphoma, sponsored by Central Hospital, Nancy, France. Not yet recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Central Hospital, Nancy, France · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
710
Sex
All
01

Study summary

The progression of small B-cell lymphomas toward a more aggressive histological form, specifically, diffuse large B-cell lymphoma (DLBCL) is a serious and most often fatal event. This process gives rise to several categories of scientific challenges :

  1. Anticipating this transformation through the early detection-while the disease is still in its indolent B-cell lymphoma stage-of biological markers that predict such a shift, particularly those that define tumor sub-clones at high risk of transformation.
  2. Identifying the specific event(s) that, within an ongoing and continuous process, trigger the definitive transition from the indolent B-cell lymphoma phase to the transformed B-cell lymphoma phase.
  3. Identifying the disrupted biological functions that drive treatment resistance in the transformed B-cell lymphoma stage, with the goal of defining new therapeutic targets.

Hypothesis :

  1. The aggressive transformation of indolent B-cell lymphomas results from an imbalance in the subclonal structure, driven by the evolution of a dominant subclone that undergoes aggressive transformation. This subclonal competition-occurring either spontaneously or under therapeutic pressure-is fueled by the acquisition and/or selection of specific molecular and epigenetic alterations, as well as favorable remodeling of the tumor microenvironment. Some of these changes are detectable as early as the indolent phase, offering the prospect of early detection, while others dictate the mechanisms of therapeutic resistance following transformation.
  2. Understanding the mechanisms of therapeutic resistance in transformed DLBCL could pave the way for the development of new, effective treatments. Furthermore, these insights could potentially be applied to resistant forms of de novo DLBCL-the most common category (40%) of B-cell lymphoma.

Our primary objective is to identify and validate the molecular, cellular, and microenvironmental alterations associated with therapeutic resistance in transformed B-cell lymphomas, and to investigate the presence of these mechanisms in resistant forms of de novo DLBCL.

Secondary objective 1. To understand the mechanisms underlying tumor evolution in each subtype of transformed B-cell lymphoma, with regard to both the characteristics of the tumor cell and its microenvironment.

Secondary objective 2. To develop cellular and animal models that mimic the transformed phase of indolent B-cell lymphomas.

Secondary objective 3. To identify biological characteristic, at the indolent B-cell lymphoma stag, that are predictive of aggressive transformation.

Read the detailed description

TYPHON-P is a regional, multicenter, longitudinal, and translational observational study based on the prospectivebuilding of a clinical-biological cohort and a centralized biobank, managed by the Lorraine Biological Resource Center and the Pathology Department of the Nancy University Hospital. The study will include patients with indolent B-cell lymphoma, transformed B-cell lymphoma, or de novo aggressive B-cell lymphoma, as well as patients for whom a non-tumor tissue sample is available to serve as a technical reference.

Clinical, biological, therapeutic, and outcome data will be collected from medical records, and residual tissue samples originally obtained for routine clinical care will be processed according to standardized pre-analytical procedures and stored for future analysis.

The program comprises three complementary analytical sub-studies:

(i) a longitudinal, paired study comparing samples from the same patient at both the indolent and transformed stages, with the aim of characterizing the mechanisms of transformation; (ii) an investigation into the association between biological characteristics and therapeutic response within various groups of transformed B-cell lymphomas, with an exploration of whether these associations can be extrapolated to de novo diffuse large B-cell lymphoma (the most common lymphoma subtype, 15% of which exhibit therapeutic resistance); (iii) a prognostic study using samples obtained at the indolent stage to identify biological characteristics associated with the subsequent risk of transformation.

Analyses will be conducted separately for each lymphoma subtype, with Richter transformation and transformed follicular lymphoma serving as the primary models, while rarer forms will be the subject of exploratory analyses. Initial discovery-phase analyses will primarily relie on available retrospective samples. The identified biological findings and signatures will subsequently be evaluated within the prospective collection, following a pre-specified validation strategy. Longitudinal follow-up, planned for a maximum duration of ten years, will serve to document disease transformation, treatments received, therapeutic response, progression, and survival. Prospective samples will undergo standardized processing in a fresh state-including, wherever possible, the preparation of viable cell suspensions-to facilitate multi-omic, single-cell, spatial, and functional analyses, as well as the development of patient-derived models.

02

Conditions studied

  • Transformed B-Cell Lymphoma
  • Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
  • Transformed Follic Lymph to Diff Large B-Cell Lymphoma

Keywords

  • Transformed B-cell lymphoma
  • Richter transformation
  • Transformed follicular lymphoma
03

In context

Lead sponsor

Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The objective is to obtain a cohort of approximately 20 to 60 analyzable cases for each subtype of transformed B-cell lymphoma, enabling the exploration of molecular alterations associated with transformation, the study of mechanisms of therapeutic resistance, and the identification of biological signatures with theranostic relevance.

For technical and methodological reasons, a control group consisting of 20 non-tumor lymph node samples will be included in this study.

Recruitment objectives:

Recruitment target for the study group: 210 patients with transformed B-cell lymphoma

Recruitment targets for the 3 control subgroups:

  • 210 patients for the group with untransformed indolent B-cell lymphoma
  • 270 patients for the group with de novo diffuse large B-cell lymphoma
  • 20 patients for the control group

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Case groups: transformed B-cell lymphomas

Inclusion criteria

Inclusion Criteria:

Patients who benefited from medical care at the University Hospital of Nancy or the Regional Hospital of Metz

-with a history of, or a current diagnosis of, one of the following five types of indolent B-cell lymphoma: CLL: chronic lymphocytic leukemia FL: follicular lymphoma MZL: marginal zone lymphoma LPL: lymphoplasmacytic lymphoma MCL: mantle cell lymphoma

Patients in whom an aggressive B-cell lymphoma is suspected and for whom a diagnostic workup (including a tumor with histopathological analysis) is underway:

Richter transformation (RT) Transformed follicular lymphoma (tFL) Transformed marginal zone lymphoma (tMZL) Transformed lymphoplasmacytic lymphoma (tLPL) Blastoid mantle cell lymphoma

  • Cases subsequently confirmed as one of the following histological variants: DLBCL (Diffuse Large B-Cell Lymphoma), Hodgkin lymphoma, or blastoid variant
  • Cases for which biological samples potentially containing tumor cells are available and confirmed to contain a significant proportion of tumor cells (> 30%)
  • Patients for whom at least one of the following types of samples is available:

Circulating blood cells, plasma, serum, any sample of cerebrospinal fluid, pleural fluid, or peritoneal fluid, biopsies performed for the diagnosis and follow-up of the lymphoma, cells extracted from these biopsies

Exclusion criteria

Exclusion Criteria:

  • Samples that do not meet the required diagnostic criteria
  • Samples that do not meet the quality criteria necessary for analysis
  • Samples that lack sufficient tumor content/representativeness for the requirements and analytical standards involved
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
710 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Case group : Transformed B-cell lymphoma

    Patients : \- who benefited from medical care at the University Hospital of Nancy or the Regional Hospital of Metz Patients with a history of, or a current diagnosis of, one of the following five types of indolent B-cell lymphoma: CLL: chronic lymphocytic leukemia FL: follicular lymphoma MZL: marginal zone lymphoma LPL: lymphoplasmacytic lymphoma MCL: mantle cell lymphoma * in whom an aggressive B-cell lymphoma is suspected and for whom a diagnostic workup-including a tumor biopsy with histopathological analysis-is currently underway: RT: Richter transformation tFL: transformed follicular Lymphoma tMZL: transformed marginal zone lymphoma tLPL: transformed lymphoplasmacytic lymphoma BL-MCL: blastoid mantle cell lymphoma * cases subsequently confirmed as one of the following histological variants: Diffuse large B-cell lymphoma, Hodgkin lymphoma, or a blastoid variant

    Other: Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma · Other: Identify, at the indolent/small-cell B-cell lymphoma stage, the biological characteristics that are predictive of aggressive transformation. · Other: investigate the existence of these mechanisms in resistant forms of de novo diffuse large B-cell lymphoma.

  • De novo aggressive lymphoma group (primarily de novo DLBCL)

    Patients: \- who benefited from medical care at the Nancy University Hospital or the Metz-Thionville Regional Hospital. Patients in whom a de novo aggressive B-cell lymphoma (DLBCL, Hodgkin lymphoma, or a blastoid variant) is suspected, and for whom a diagnostic workup-including a tumor biopsy with histopathological analysis-is currently underway * with no prior history or concurrent diagnosis of a small B-cell lymphoma * for whom biological samples are available and confirmed to contain an adequate proportion of tumor cells (\> 30%) These samples will be collected either as part of the diagnostic workupor during the course of follow-up

    Other: investigate the existence of these mechanisms in resistant forms of de novo diffuse large B-cell lymphoma.

  • Indolent/small-cell non-transformed B-cell lymphomas group

    Patients : * who benefited from medical care at the Nancy University Hospital or the Metz Regional Hospital * presenting with an indolent B-cell lymphoma, still untransformed at the corresponding index date, with a documented follow-up duration at least equal to the time interval between the diagnosis of the indolent lymphoma and the transformation observed in the transformed cases * for whom biological samples potentially containing tumor cells are available and contain an adequate proportion of tumor cells (\> 30%) These samples will be collected either during the diagnostic work-up or during the course of follow-up

    Other: Identify, at the indolent/small-cell B-cell lymphoma stage, the biological characteristics that are predictive of aggressive transformation.

  • Non-tumor patient" control group / lymph node tissue and blood free of tumor cells

    Patients: * who benefited from medical care at the Nancy University Hospital or the Metz Regional Hospital * for whom one or more blood samples, serous fluid samples, and/or lymph node samples are available (either collected for suspected lymphoma or exploratory purposes, such as sentinel lymph node in solid-tumor oncology) * for whom the hypothesis of lymphoma or metastasis of solid cancer has been ruled out based on anatomopathological analysis (non-tumor samples)

    Other: Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma · Other: Identify, at the indolent/small-cell B-cell lymphoma stage, the biological characteristics that are predictive of aggressive transformation. · Other: investigate the existence of these mechanisms in resistant forms of de novo diffuse large B-cell lymphoma.

Interventions

  • OtherIdentification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma

    Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma-categorized as good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease)-defined in a discovery cohort and subsequently validated in an independent cohort, with an assessment of effect size, reproducibility, and discriminative value.

  • OtherIdentify, at the indolent/small-cell B-cell lymphoma stage, the biological characteristics that are predictive of aggressive transformation.

    Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort.

  • Otherinvestigate the existence of these mechanisms in resistant forms of de novo diffuse large B-cell lymphoma.

    Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group.

06

What researchers measure

Primary outcomes

  1. To identify and validate the molecular, cellular, and microenvironmental alterations associated with therapeutic resistance in transformed B-cell lymphomas, and to investigate the presence of these mechanisms in resistant forms of *de novo* DLBCLs

    Outcome measure 1 : correlation between gene expression profiles at agressive stage, and response to treatment. Measurement : whole transcriptome profiling by RNA-sequencing Unit of measure : transcripts rates Outcome measure 2 : correlation between protein expression profiles at agressive stage, and response to treatment. Measurement : protein expression by liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein Outcome measure 3 : correlation between tumor microenvironment, and response to treatment. Measurement : microenvironment profiling by flow cytometry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-cells, CD8+ T-cells, macrophages) Treatment responses : good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease). Signatures will be defined in a discovery cohort and subsequently confirmed in an independent cohort.

    Time frame: 10 years

Secondary outcomes

  1. Identify, at the indolent/small-cell B-cell lymphoma stage, the biological characteristics that are predictive of aggressive transformation.

    The analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Outcome measure 1 : correlation between gene expression profiles at indolent stage, and the occurence of agressive transformation. Measurement : whole transcriptome profiling Measurement tool : RNA-sequencing Unit of measure : transcripts rates Outcome measure 2 : correlation between DNA methylation profiles at indolent stage, and the occurence of agressive transformation. Measurement : whole methylome profiling Measurement tool : long read whole genome sequencing Unit of measure : methylation rates for 28 billion sites Outcome measure 3 : correlation between proteomic profiles at indolent stage, and the occurence of agressive transformation. Measurement : protein expression Measurement tool : liquid chromatography coupled with mass spectrometry Unit of measure : absolute numbers for each protein

    Time frame: 10 years

  2. Develop cellular and animal models that mimic the transformed phase of indolent B-cell lymphomas.

    Outcome measure 1 : gene expression profiles concordance between patient-derived experimental models and the original tumors. Measurement : whole transcriptome profiling by RNA-sequencing Unit of measure : rate of transcripts Outcome measure 2 : protein expression profiles concordance between patient-derived experimental models and the original tumors. Measurement : protein expression by liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein Outcome measure 3 : tumor microenvironment profiles concordance between patient-derived experimental models and the original tumors. Measurement : microenvironment profiling by flow cytometry or immunohistochemistry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-lymphocytes, CD8+ T-lymphocytes, CD25+ T-lymphocytes, macrophages)

    Time frame: 10 years

  3. To understand the mechanisms underlying tumor evolution in each subtype of transformed B-cell lymphoma, with regard to both the characteristics of the tumor cell and its microenvironment.

    Outcome measure 1 : modification of gene expressions in malignant cells between the indolent stage, and the agressive transformation. Measurement : gene expression Measurement tool : whole transcriptome sequencing (RNA-seq) Unit of measure : transcripts rates Outcome measure 2 : modification of protein expressions in malignant cells between the indolent stage, and the agressive transformation. Measurement : protein expression Measurement tool : liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein Outcome measure 3 : modification of tumor microenvironment between the indolent stage, and the agressive transformation. Measurement : microenvironment profiling Measurement tool : flow cytometry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-lymphocytes, CD8+ T-lymphocytes, CD25+ T-lymphocytes, macrophages)

    Time frame: 10 years

07

Study locations

1 site
08

References and documents

Publications

  • Ten Hacken E, Sewastianik T, Yin S, Hoffmann GB, Gruber M, Clement K, Penter L, Redd RA, Ruthen N, Hergalant S, Sholokhova A, Fell G, Parry EM, Broseus J, Guieze R, Lucas F, Hernandez-Sanchez M, Baranowski K, Southard J, Joyal H, Billington L, Regis FFD, Witten E, Uduman M, Knisbacher BA, Li S, Lyu H, Vaisitti T, Deaglio S, Inghirami G, Feugier P, Stilgenbauer S, Tausch E, Davids MS, Getz G, Livak KJ, Bozic I, Neuberg DS, Carrasco RD, Wu CJ. In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities. Blood Cancer Discov. 2023 Mar 1;4(2):150-169. doi: 10.1158/2643-3230.BCD-22-0082. PubMed 36468984 ↗
  • Broseus J, Hergalant S, Vogt J, Tausch E, Kreuz M, Mottok A, Schneider C, Dartigeas C, Roos-Weil D, Quinquenel A, Moulin C, Ott G, Blanchet O, Tomowiak C, Lazarian G, Rouyer P, Chteinberg E, Bernhart SH, Tournilhac O, Gauchotte G, Lomazzi S, Chapiro E, Nguyen-Khac F, Chery C, Davi F, Hunault M, Houlgatte R, Rosenwald A, Delmer A, Meyre D, Bene MC, Thieblemont C, Lichter P, Ammerpohl O, Gueant JL; ICGC MMML-Seq Consortium; Guieze R, Martin-Subero JI, Cymbalista F, Feugier P, Siebert R, Stilgenbauer S. Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis. Nat Commun. 2023 Jan 19;14(1):309. doi: 10.1038/s41467-022-34642-6. PubMed 36658118 ↗
  • Parry EM, Lemvigh CK, Deng S, Dangle N, Ruthen N, Knisbacher BA, Broseus J, Hergalant S, Guieze R, Li S, Zhang W, Johnson C, Long JM, Yin S, Werner L, Anandappa A, Purroy N, Gohil S, Oliveira G, Bachireddy P, Shukla SA, Huang T, Khoury JD, Thakral B, Dickinson M, Tam C, Livak KJ, Getz G, Neuberg D, Feugier P, Kharchenko P, Wierda W, Olsen LR, Jain N, Wu CJ. ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell. 2023 Oct 9;41(10):1803-1816.e8. doi: 10.1016/j.ccell.2023.08.013. Epub 2023 Sep 21. PubMed 37738974 ↗
  • Parry EM, Leshchiner I, Guieze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Broseus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, Yin S, Deng S, Slowik K, Jacobs R, Huang T, Li S, Fell G, Redd R, Lin Z, Knisbacher BA, Livitz D, Schneider C, Ruthen N, Elagina L, Taylor-Weiner A, Persaud B, Martinez A, Fernandes SM, Purroy N, Anandappa AJ, Ma J, Hess J, Rassenti LZ, Kipps TJ, Jain N, Wierda W, Cymbalista F, Feugier P, Kay NE, Livak KJ, Danysh BP, Stewart C, Neuberg D, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu CJ. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023 Jan;29(1):158-169. doi: 10.1038/s41591-022-02113-6. Epub 2023 Jan 9. PubMed 36624313 ↗

Individual participant data

Plan to share: Yes — Anonymized samples and clinical data will be shared with companion research teams. Material and/or data transfer agreements will be signed between the University hopital of Nancy (promoter) and the associated research teams.

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: Start date : inclusion date end date : end of the study (decembre 2036)

Access criteria: Material and/or data transfer agreements will be signed between the University hopital of Nancy (promoter) and the associated research teams. Data will be transfered with secured transfer protocols.

Data sharing details ↗ · www.chru-nancy.fr

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2036, 120 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 19, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2036
CompletionEst.
Dec 1, 2036
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948213
Responsible party
Julien BROSÉUS (Professor, Central Hospital, Nancy, France) — Principal investigator
First posted
Nov 19, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2036 (estimated)
Completion
Dec 1, 2036 (estimated)
Last update
Nov 19, 2026

Study contacts

Julien BROSÉUS, Professor
Contact
j.broseus@chru-nancy.fr
+33 03 83 15 49 14

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion